Prospective postmarket device studies versus returned product analysis as a predictor of system survival

PACE - Pacing and Clinical Electrophysiology

Volumn 23, Issue 7, 2000, Pages 1150-1155

  Pratt, Timothy R H ^a,b   Pulling, Christopher C ^a   Stanton, Marshall S ^b  

^a Dept of Tachyarrhythmia Clin/O ^*  (United States)

^b MEDTRONIC INC   (United States)

Author keywords

Adverse events; Chronic performance; Device survival; Monitoring; RPA

Indexed keywords

ARTICLE; DEFIBRILLATOR; GRAFT SURVIVAL; POSTMARKETING SURVEILLANCE; PROSTHESIS FAILURE; QUALITY CONTROL;

EID: 0033927030     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2000.tb00916.x     Document Type: Article

References (19)

1. 1. Pratt TRH, Pulling C. Tachyarrhythmia Product Performance Report (Number 5, May 99) Medtronic Inc. UC9603644eEN.
2. 2. Guidant/CPI, 1999, Cardiac Rhythm Management Product Performance Report.
3. 3. Fisher LD, Van Belle G. Biostatistics: A Methodology for the Health Sciences. New York, John Wiley & Sons, 1993.
4. 4. Guidant/CPI, 1997, Cardiac Rhythm Management Product Performance Report, 1997, p. 9.
5. 5. Peralta AO, John RM, Martin DT, et al. Long term performance of the Endotak C defibrillator lead. Circulation 1998; 98:1-787.
6. 6. Pulling C, Pratt TRH. 1999 Internal Review of Medtronic Tachyarrhythmia Chronic: Systems Study Database.
7. 7. Rothman KJ. Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chronic Dis 1978; 31:557-560.
8. 8. Returned Product Analysis Event Analysis Reporting System, Medtronic US Tachy Lead Performance Summary through 31 Jan 99.
9. 9. Pratt TRH, Pulling C. Tachyarrhythmia Product Performance Report (Number 5, May 99) Medtronic Inc. UC9603644eEN, p. 8.
10. 10. Song SL. The Bilitch Report: Part A and B, Performance of Implantable Cardiac Rhythm Management Devices. PACE 1993; 16:814-827.
11. 11. Kawanishi DT, Song SL, Furman S, et al. Failure rates of leads, pulse generators, and programmers have not diminished over the last 20 years: Formal monitoring of performance is still needed. PACE 1990; 19:1819-1823.
12. 12. Minneapolis Heart Institute sponsored Pacemaker and ICD Registry Information. Available at: http://pacemakerandicdregistry. com/index.htm as at 15DEC99.
13. 13. Danish Pacemaker and ICD Registry Website Information. Available at: http://pacemaker.dk/icdorganisation.html. Accessed March 26, 1999.
14. 14. Byrd CL, Sehwartz SJ, Hedin NB. Lead extraction: Techniqnes and indications. In SS Barold, J Mugica (eds.): New Perspectives in Cardiac Pacing, 3rd edition. Armonk NY, Futura Publishing Co., Inc., 1993.
15. 15. Smith HJ. Fearnot NE, Byrd CL, et al. Five years experience with intravascular lead extraction. PACE 1994; 17:2016-2020.
16. 16. Wilkoff BL, Byrd CL, Love CJ, et al. Pacemaker lead extraction with the laser sheath: results of the pacing lead extraction with the excimer sheath (PLEXUS) trial. J Am Coll Cardiol, 1999; 33: 1671-1676.
17. 17. Colavita PG, Zimmerman SH, Gallagher JJ, et al. Intravascular extraction of chronic pacemaker leads: Efficacy and follow-up. PACE 1903; 16:2333-2336.
18. 18. Narula DD, Steinburg JS, Ehlert FA, et al. Actuarial survival of CPI epicardial and endocardial defibrillation and rate sensing leads. Circulation 1997; 96:1-694.
19. 19. Brady PA, Friedman PA, Trusty JM, et al. High Failure rate for an epicardial implantable cardioverter-defibrillator lead: Implications for long-term follow-up of patients with an implantable cardioverter-defibrillator. J Am Coll Cardiol 1098; 31:616-622.